Latest Articles
Adiposity, Metabolites Linked to Endometrial Cancer - BIOENGINEER.ORG
Adiposity, Metabolites Linked to Endometrial Cancer BIOENGINEER.ORG
Published: Oct. 21, 2025, 2:27 p.m.
Comparison of identification of sentinel lymph nodes between ICG vs methylene blue in v notes staging surgery for endometrial cancer - BMC Surgery
Comparison of identification of sentinel lymph nodes between ICG vs methylene blue in v notes staging surgery for endometrial cancer BMC Surgery
Published: Oct. 21, 2025, 11:10 a.m.
New noninvasive endometriosis tests are on the rise - StartupNews.fyi
New noninvasive endometriosis tests are on the rise StartupNews.fyi
Published: Oct. 21, 2025, 10:28 a.m.
New noninvasive endometriosis tests are on the rise - MIT Technology Review
New noninvasive endometriosis tests are on the rise MIT Technology Review
Published: Oct. 21, 2025, 10 a.m.
Endogene.bio Study Validates Menstrual Blood Approach for Endometriosis Detection - Femtech Insider
Endogene.bio Study Validates Menstrual Blood Approach for Endometriosis Detection Femtech Insider
Published: Oct. 21, 2025, 8:12 a.m.
Comparison of sociodemographic factors, lifestyle, and gastrointestinal symptoms between patients with endometriosis and IBS - BMC Gastroenterology
Comparison of sociodemographic factors, lifestyle, and gastrointestinal symptoms between patients with endometriosis and IBS BMC Gastroenterology
Published: Oct. 21, 2025, 7:07 a.m.
‘Great first step’ – advocates react to new national endometriosis framework - The Irish Independent
‘Great first step’ – advocates react to new national endometriosis framework The Irish Independent
Published: Oct. 21, 2025, 4:30 a.m.
Endometriosis rates double in 10 years, new research reveals - bodyandsoul.com.au
Endometriosis rates double in 10 years, new research reveals bodyandsoul.com.au
Published: Oct. 21, 2025, 1:04 a.m.
What If We Took Endometriosis as Seriously as We Take Diabetes? - Women's eNews
What If We Took Endometriosis as Seriously as We Take Diabetes? Women's eNews
Published: Oct. 20, 2025, 6:42 p.m.
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen - The AI Journal
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen The AI Journal
Published: Oct. 18, 2025, 10:28 a.m.
Link copied to clipboard!